Vivek Jha

Ever met Rajeev? 🇮🇳 🤔 He's a top pharma sales director, juggling targets, team challenges, and now...AI? 🤯 Rajeev isn't alone. Most Indian pharma sales leaders feel the same: 𝗢𝘃𝗲𝗿𝘄𝗵𝗲𝗹𝗺𝗲𝗱: Large language models (LLMs) sound amazing, but where to start? 𝗨𝗻𝘀𝘂𝗿𝗲: How can AI actually boost sales, beyond the buzzwords? 𝗪𝗼𝗿𝗿𝗶𝗲𝗱: Will falling behind on this tech mean falling behind the competition? Rajeev was stuck, until he discovered... 𝗧𝗵𝗲 𝗟𝗟𝗠 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽 𝗧𝗵𝗮𝘁 𝗖𝗵𝗮𝗻𝗴𝗲𝗱 𝗘𝘃𝗲𝗿𝘆𝘁𝗵𝗶𝗻𝗴 🚀 It's not just about the tech. It's about YOU – your team, your goals, YOUR success. 💪 This workshop isn't a lecture, it's a game-changer, designed for: 𝗭𝗼𝗻𝗮𝗹 𝗠𝗮𝗻𝗮𝗴𝗲𝗿𝘀, 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗦𝗮𝗹𝗲𝘀 𝗠𝗮𝗻𝗮𝗴𝗲𝗿𝘀: Translate AI into real-world strategies. 𝗖-𝗦𝘂𝗶𝘁𝗲 𝗟𝗲𝗮𝗱𝗲𝗿𝘀: Empower your entire sales force with cutting-edge tools. 𝗔𝗻𝘆𝗼𝗻𝗲 𝘄𝗵𝗼 𝘄𝗮𝗻𝘁𝘀: To unlock AI's power for smarter decisions and BIGGER wins. Here's the magic 🪄: 𝗗𝗲𝗰𝗼𝗱𝗲 𝘁𝗵𝗲 𝗔𝗜 𝗝𝗮𝗿𝗴𝗼𝗻: We'll break it down in simple terms, no tech degree needed. 𝗛𝗮𝗻𝗱𝘀-𝗢𝗻 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲: Learn by DOING, with real pharma sales scenarios. 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: Your challenges, your team – we tailor the training to YOU. What's in it for YOU? 🤔 𝗟𝗮𝘀𝗲𝗿-𝗙𝗼𝗰𝘂𝘀𝗲𝗱 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: Uncover hidden patterns in your sales data. 🎯 𝗪𝗼𝗿𝗱𝘀 𝗧𝗵𝗮𝘁 𝗪𝗼𝗿𝗸: Craft pitches that connect, emails that convert, and reports that impress. 📈 𝗟𝗲𝘀𝘀 𝗧𝗶𝗺𝗲 𝗼𝗻 𝗧𝗲𝗱𝗶𝗼𝘂𝘀 𝗧𝗮𝘀𝗸𝘀: Let AI handle the boring stuff, so your team can focus on what they do best. 🙌 𝗟𝗲𝗮𝗱 𝘄𝗶𝘁𝗵 𝗖𝗼𝗻𝗳𝗶𝗱𝗲𝗻𝗰𝗲: Understand your team's needs, guide them better, and watch them soar. 🚀 Imagine Rajeev... Confidently using AI to predict market trends and plan smarter campaigns. 😎 Motivating his team with data-backed insights and personalized coaching. 💪 Hitting those targets, exceeding expectations, and leading the way in pharma sales. 🏆 That could be YOU! Ready to take the next step? 👉 Click here https://lnkd.in/gnpNHfpT to learn more about the LLM workshop and secure your spot. 👈 𝗗𝗼𝗻'𝘁 𝗴𝗲𝘁 𝗹𝗲𝗳𝘁 𝗯𝗲𝗵𝗶𝗻𝗱. 𝗘𝗺𝗯𝗿𝗮𝗰𝗲 𝘁𝗵𝗲 𝗔𝗜 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘂𝗻𝗹𝗼𝗰𝗸 𝘆𝗼𝘂𝗿 𝗳𝘂𝗹𝗹 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹.

7

The RSSDI - Research Society for the Study of Diabetes in India (RSSDI) and the Koita Foundation have forged a strategic partnership to inaugurate the RSSDI-Koita Centre for Digital Diabetology (KCDD). This collaboration aims to advance #diabetesmanagement and research through innovative digital solutions. The Memorandum of Understanding (#MoU) was formalized in the presence of esteemed dignitaries including Dr. Rakesh Sahay, President of RSSDI, Dr. Sanjay Agarwal, #SecretaryGeneral of RSSDI, Rekha Koita, Director of Koita Foundation, and Surabhi Goel, Chief Operating Officer of Koita Foundation. The signing ceremony took place during the RSSDI - Research Society for the Study of Diabetes in India Annual Research Retreat 2024 in Jaipur on April 13, 2024. RSSDI is the largest association of physicians dedicated to diabetes care in Asia, boasting over 11,500 members across 23 states in India. On the other hand, the Koita Foundation is a non-profit organization committed to advancing digital health adoption and NGO transformation in India. RSSDI-KCDD marks a pioneering endeavor in digital diabetology, aiming to leverage technology to enhance various aspects of diabetes care: Quality Improvement: Utilizing digital tools such as Electronic Medical Records (EMRs) and artificial intelligence (AI) to enhance treatment workflows, patient engagement, and adherence to clinical guidelines. Affordability: Identifying opportunities for cost reduction through data sharing and technology adoption to make diabetes care more accessible and affordable. Access Enhancement: Leveraging telemedicine and digital solutions to improve access to high-quality diabetes care, especially in rural and non-urban areas. Productivity Enhancement: Streamlining clinical and administrative workflows through digital automation to boost efficiency and reduce manual tasks. Best Practices: Identifying and disseminating best practices in digital technology for diabetes management. Training and Capacity Building: Providing continuous learning opportunities and skill development for healthcare professionals through digital platforms. Research and Development: Collaborating with healthcare startups, pharmaceutical companies, and other organizations to drive research and development initiatives in diabetes care. Dr. Rakesh Sahay emphasized the significance of this initiative in advancing diabetes care management, particularly in addressing challenges related to timely and accurate patient data. Dr. Sanjay Agarwal underscored the importance of leveraging digital tools to support patients, healthcare professionals, and systems. #News #Medlr #Healthnews #Healthcare #Health

1

Nonagenarians Healthcare Ecosystem: An existing problem in the west and an emerging problem in our part of the world #Nonagenarians #Healthcare A ecosystem that works in the west may not necessarily work for us due to the cultural differences. Nonagenarians care in India will soon (within 10-15 years) need a huge ecosystem backed by the Government that could take care of their unique needs and preferences to help them maintain optimal health and quality of life. The ecosystem will need to be equipped with technological solutions that are both green and help reduce the cost of care, providing them with some financial relaxation by getting support from Government Policies. Below are few aspects of the nonagenarian ecosystem: 1. Technologically Integrated and Regular Healthcare Services: - Regular Medical Check-ups - Preventive Care - Pharmacy Services - Telemedicine - Health Monitoring - Communication Tools 2. Daily Health Routine: - Tailored Exercise Programs - Rehabilitation Services - Nutritional Support 3. Mental and Cognitive Training: - Cognitive Training - Mental Health Services 4. Senior Proof Housing Services: - Home Modifications - Assistive Devices - Emergency Services 5. Personalized Care: - Care Coordination - Individualized Care Plans 6. Community and Social Support: - Senior Centers - Social Engagement - Volunteer Services 7. Education and Awareness: - Health Education - Family Caregiver Support 8. Holistic Approaches: - Complementary Therapies - Spiritual and Emotional Support Few areas and products that are used by the Nonagenarians: - Mobility : Walker, Walking Stick, Mobility Scooters, Wheel Chair, Crutches, Power Knee, Grabber, Electric Kitchen Tools, Ramps, Shower, Bath, Commode Chair, Motion Sensor Lights, Overbed Table, Height Adjustable Bed (Electrically Powered Or Manual), Anti Slip Socks and Slippers - Visual : Antiglare Glasses, Non Slip Table Mats, USB Talking Book Player, Talking Clocks, Talking Watches, Electronic Magnifier, Rechargable LED pocket Light, High Lumens Bulb - Audio : Hearing Aids (BTE, ITE and Canal), Cochlear Implants, Assistive Listening Devices (ALDs), Augmentative and alternate communication Devices (AAC), Alerting Devices - Hygiene : Wet Wipes, Adult Diapers (Nappy Style and Pull Ups or Pant style), Disposable Underpads, Disposable Bed Sheets, Adaptive clothing with Velcro closure and elastic waistbands - Monitoring : BP Monitors, Blood Glucose Monitors, Pulse Oximeter, Weighing Scale, Digital Thermometer - Respiratory : Oxygen Concentrator, CPAP Machine - Medication : Pill Organizer, Automated Pill Dispenser, Pill Crusher, Nebulizer Many of the above products needs to be customized based on the individual needs and requirements. AI In Healthcare.

16

1 Comment

Thoughts on this? >> How To Select The Right Flexi-Cap Scheme For Your Portfolio—The Mutual Fund Show >> Comment below! >>> lqventures.com #digitalhealth #socialmedia #digitalmarketing #healthtech #industry40 #mhealth #AI #IoT

1

Pleasure to share that 4th time in a row, I am on board as Jury Member for Economic Times AWARDS. This time it is ET HEALTH AWARDS 2024, where Grand Thornton Bharat are tabulator partners, the previous ones being ET PHARMA 2023, ET HEALTH 2023 & ET RE-PHARMA 2024, where E&Y LLP were the Tabulator partners. Am indeed amazed & glad to see how fast our Hospitals across India have embraced latest Hi tech equipments especially Robots, latest Softwares and have been very creative in resolving complicated cases. In house programs for Patient safety, ingenous safe innovative methods to avoid surgery / complicated surgery, etc..shows the creativity, passion to serve, putting patient first by the Management & Staff, equally. Lots of learning too while determing winners. We only lack in manufacturing the Hi tech high cost machineries, which the big Hospitals import. Time to focus there under "Atma Nirbhar Bharat " or atleast a PLI Scheme for indigenous manufacturing & exports. With nominations closed, Jury rankings locked last week, wishing that the most deserving ones in all categories get the prestigious🏆at Hotel Crowne Plaza, Gurugram on 27th Sept.2024.#ETHEALTH, #ETHEALTHAWARDS2024, #HEALTH,#HOSPITAL,#PLISCHEME,#ATMANIRBHARAT,#ROBOTICSURGERY.

21

12 Comments

🔊 Stay ahead with latest updates on ADC and Strategic Moves in Oncology 🚀 📅 Alphamab Oncology presented data at SITC 2024 on JSKN033 (HER2 ADC), showing a strong safety profile and anti-cancer activity, bolstering IO and ADC combination potential. 📅 Innate Pharma shared preclinical insights on IPH45 (Nectin-4 ADC) at SITC 2024, confirming IND submission is planned for later this year. 📅 Cantargia AB revealed promising synergy between nadunolimab and ADCs at SITC 2024, enhancing anti-tumor effects while reducing neuropathy. 🧪 Zymeworks Inc. dosed its first patient in a Phase 1 trial of ZW191 (FR⍺ ADC) targeting advanced FR⍺-expressing solid tumors. 🎯 Elevation Oncology progresses with its HER3-ADC development, with Phase 1 dosing set for Q4 2024 and upcoming data presentations at ESMO-IO 2024. 🤝 Vaccinex collaborates with Amgen, Merck, and others to advance ADCs and immunotherapies using ActivMAb® technology. 🤝 Daiichi Sankyo US and ALTEOGEN Inc. ink a $300M partnership to develop a subcutaneous version of Enhertu (HER2 ADC), promising easier administration. 🤝 NJ Bio, Inc. and Charles River Laboratories join forces to accelerate ADC manufacturing and clinical development. 🧪 SystImmune’s BL-M17D1 (CD138 ADC) received FDA IND clearance, setting the stage for a Phase 1 trial in advanced solid tumors. 💰 Akari Therapeutics, Plc secures shareholder approval for its merger with Peak Bio, focusing on ADC and GA platforms post-closure on November 13. 🎯 WuXi Biologics wins "Best CDMO" at the 2024 World ADC Awards, with nominations for "Best ADC Platform Technology" and "Best CRO." 📅 Mabwell presented data on 7MW4811 (Nectin-4 ADC) at the World ADC Conference 2024, showing strong anti-tumor activity in GI cancers. 📅 Sutro Biopharma, Inc. showcased five ADC innovations at the 15th Annual World ADC Conference, marking significant advancements in the field. 🎯 NextCure, Inc. shared preclinical data on LNCB74 (B7-H4 ADC) for colorectal cancer at SITC 2024, with an IND filing planned by year-end. 📅 ADC Therapeutics to present ZYNLONTA (CD19 ADC) data in R/R FL and MZL at the upcoming ASH Annual Meeting 2024. 📅 Heidelberg Pharma AG to reveal new Phase 1/2a data on HDP-101 (Amanitin ADC) for RRMM at ASH 2024. 📅 CStone Pharmaceuticals will share clinical data on CS5001 (ROR1 ADC) for lymphoma at ASH 2024. 📅 BostonGene presented a poster on novel ADC targets in sarcomas at SITC 2024 using RNA sequencing insights. 📅 Pyxis Oncology to host a virtual investor event on November 20, 2024, discussing early Phase 1 data on PYX-201 (EDB+FN ADC). 🤝 Biocytogen licenses its B7H3/PTK7 Bis ADC program to IDEAYA Biosciences, positioning IDE034 as a global development candidate. ADC advancements continue to drive forward the oncology landscape with impactful preclinical and clinical insights, strategic partnerships, and promising therapeutic innovations! #oncology #ADCs #biotechnology #pharmaceuticals

24

A simple and interesting book by dear Anuradha Buvaraagan. "The primary objective of this book is to get across the following extremely important message, which will help unlock up the gates to happiness, peace, and optimal health. An optimistic mindset, also known as positive thinking, involves emphasising the positive aspects of any given circumstance. The greatest approach to inwardly motivating oneself to follow our dreams is to think positively. It offers contentment, inner serenity, prosperity, stronger bonds with others, greater health, and happiness. Additionally, it facilitates the flow of daily life and adds brightness and promise to it. The secret to humanity's soul lies within Mother Nature, in all her splendour and beauty. Actually, we are bonded and guided by her inherent grandeur and harmony. Mother Earth has much to teach us about the value of stillness and meditation. Through the practice of unconditional sharing and receiving, we can develop the ability to provide and accept safe haven from others. I pray for universal synchronisation. Best regards, Anuradha" I recommend it. please check it on this Amazon link https://amzn.eu/d/1x6rfHe

6

3 Comments

Why Accessibility is an Ethical Imperative In a country as diverse as India, healthcare inequality is a persistent challenge. If gene therapy remains the privilege of the wealthy, it risks exacerbating existing social and economic disparities. Everyone, regardless of their financial background, should have the right to access life-saving treatments. Gene therapy, with its potential to cure or dramatically alleviate chronic conditions, must not become a tool that further entrenches healthcare inequity. What Needs to Be Done 1. Government Subsidies and Pricing Regulations: The Indian government must consider policies that subsidize the cost of gene therapies, similar to how it has provided free or affordable access to essential medicines like antiretrovirals for HIV patients. Pricing regulations could also ensure that pharmaceutical companies do not charge exorbitant rates. 2. Public-Private Partnerships: Collaborative efforts between the government and private industry can help scale production, streamline research, and lower costs. In India, where government-funded health schemes such as Ayushman Bharat are beginning to improve healthcare access, incorporating gene therapy into such frameworks could be a game-changer. 3. Local Research and Development: Encouraging local R&D in gene therapy through increased funding for biotechnology and medical institutions would help reduce dependency on expensive foreign treatments. India’s strength in the generic pharmaceutical industry proves that it has the potential to become a global hub for affordable gene therapies as well. 4. Raising Awareness and Education: Educating both healthcare professionals and the general public about gene therapy’s potential is essential. Widespread understanding can lead to greater acceptance, demand for fair pricing, and pressure on policymakers to ensure broader access. A Call to Action India’s healthcare system is already under strain due to the dual burden of infectious and non-communicable diseases. However, gene therapy presents an opportunity to revolutionize treatment for genetic disorders and chronic illnesses. To fully realize this potential, it is critical that these treatments be accessible to everyone, not just the privileged few. Access to gene therapy should not be a matter of wealth but a matter of human rights. In a country committed to equity and inclusive growth, ensuring universal access to gene therapy can pave the way for a healthier, more equitable future.

15

1 Comment

Dr Reddy is well known name in the pharma space, the Indian Company has over several decades built a sizeable global generics business but has in more recent years invested in developing an innovative medicines business. The company caught my eye last week when they announced the launch of DTx product Nerivio in Europe to treat migraine. The product was launched in India in 2023 and the launch in Europe represents an expansion of business model to new markets (info here: https://lnkd.in/gBXvdiHU). Literally 2 weeks later the company announces the launch of a second DTx product, this time for the management of irritable bowel syndrome (IBS) via an integrated care model. I was surprised by these moves firstly because Dr Reddy is more well known for its generics business and not innovative solutions. Secondly the company is using an integrated care model rather than just selling the DTx product. This is eye opening since pharma companies don't really have that much expertise managing patients, their core competency rests in selling drugs to doctors and other medical channels. To put this into context Dr Reddy is putting together a care program that involves coordinating the use of a team of nutritionists, psychologists and health coaches. It also is designed to work closely with clinicians by supporting patients receiving standard of clinical care. The program ticks a number of important boxes in the use of digital health products; (i) work in collaboration with HCPs, (ii) be interoperable, (iii) deliver personalised care, (iv) provide an holistic care model. The last four points sum-up Peach Health Asia's approach to commercialising patient facing digital health products in Asia. Its great to see innovation on the digital health front coming out of different parts of the world, and as I've said before for those interested in this space India is place to keep an eye on. #Digitalhealth #digitaltherapeutics #digitalhealthcare

45

Tarun Kumar from Novartis says ‘The Omni Advantage' is a must read! How amazing is that. 😊 “The Omni Advantage presents a compelling framework tailored specifically for the pharmaceutical industry, offering a strategic roadmap to navigate the complexities of multichannel engagement in healthcare. Through meticulous research and real-world case studies, the book illustrates how pharmaceutical companies can leverage omnichannel strategies to enhance patient care, optimise sales and marketing efforts, and foster stronger stakeholder relationships. A must-read for pharmaceutical executives and professionals seeking to harness the full potential for omnichannel engagement in today's evolving healthcare landscape." Thank you, Tarun! Get your copy 👇 📙https://lnkd.in/ePcDEW56 #TheOmniAdvantage #Pharma #Pharmaceuticals

10

🌐 Industry Profile Series: Innovating in India – Bharat Serums and Vaccines Limited🌐 Explore how Bharat Serums and Vaccines Limited (BSV) is advancing healthcare through innovative biopharma solutions tailored for critical care and women's health! 💉🌍 🚀 Key Insights: 🔬 Core Focus: Addressing critical care needs, women's health, and producing biotechnology-derived products to enhance healthcare solutions. 👩‍⚕️🧬 🧪 Technologies Used: Expertise in producing blood-derived products, antibodies, therapeutic proteins, and developing biosimilars. Cutting-edge technology is employed to ensure quality and effectiveness in healthcare treatments. 🧬💉 🎯 Mission: Committed to making advanced biopharma products accessible while raising healthcare standards globally. 🌟 🎓 Student Opportunities: Offers internships in biopharma R&D, clinical trials, antibody production, critical care therapeutics, and biosimilars, providing students with hands-on industry experience. 👩‍🔬👨‍🔬 🔧 Services Offered: Specializes in critical care medications, biosimilars, women’s health, assisted reproduction, and therapies involving antibodies and blood plasma. 💊🩺 📊 Strategies: Focused on developing cost-effective, life-saving therapies in critical care, women’s health, fertility solutions, and blood-derived treatments. 🌏 Learn more about BSV’s contributions to healthcare: [https://lnkd.in/gy2Sbumd) 💫 Credits: Poster: Shruti Gajbhiye Content: Binny Bipasha Das #BSV #HealthcareInnovation #Biopharma #CriticalCare #InnovationInIndia #NextGenScience

1

Today's The Times Of India published a report from The Lancet is talking about worsening patients outcome in developed countries where regularity norms are strict. Now just imagine what is going on here in India. Private hospitals are taking YoY minimum growth target at 20% come what may. Doctors are forced to generate revenue as per corporate practice and in the name of treatment. What to do? Model of BUSINESS is like that only.

7

Thoughts on this? >> MMRDA Appoints Contractors For Road Projects Worth Rs 12,500 Crore >> Comment below! >>> lqventures.com #digitalhealth #socialmedia #digitalmarketing #healthtech #AI #IoT #mhealth #industry40

2

India's GLP-1 market is promising to improve diabetes management, but key barriers need addressing. According to GRG Health’s recent study, while GLP-1 therapies offer enhanced glycemic control and weight management, challenges like high costs, limited accessibility, and low awareness restrict broader adoption. The study highlights that diabetologists and endocrinologists primarily drive prescriptions, with general practitioners favoring traditional treatments. To unlock the potential of this market, targeted strategies such as cost reductions, education programs, and patient awareness initiatives are essential. Additionally, enhancing distribution and accessibility, especially in rural areas, is critical. Collaborative efforts among pharmaceutical companies, healthcare providers, and policymakers can drive market growth and improve patient outcomes. #DiabetesManagement #GLP1Therapies #Pharmaceuticals #HealthcareInnovation #PatientOutcomes #ChronicDiseaseCare #MarketGrowth #Endocrinology #HealthcareAccess #Diabetology #PatientAwareness #HealthEquity #RuralHealthcare #MedicalResearch #HealthcareIndia

28